Regor Therapeutics Announces Completion of $90 Million Series B Financing
Regor Therapeutics Announces Completion of $90 Million Series B Financing
  • 스타트업엔(StartupN)
  • 승인 2021.02.19 13:13
  • 댓글 0
이 기사를 공유합니다

Regor Therapeutics, a clinical stage biotechnology company dedicated to the discovery of innovative medicines to treat cancer, immune disorders and metabolic diseases, announces the successful completion of $90 million Series B financing.

Founded in July of 2018 by a group of veteran drug hunters with extensive research and executive leadership experiences at top multinational pharmaceutical companies, Regor aims to establish world-class innovation capabilities and is committed to delivering clinically differentiated, best- and first-in-class drugs to serve patients globally.  By leveraging CARD, Computer Accelerated Rational Discovery, a proprietary enabling technology platform, the team has successfully advanced numerous discovery programs in a dramatically accelerated fashion, including from ideas to a clinical start in two years.  

The Series B financing was led by Lilly Asia Ventures and included participation from Loyal Valley Capital, Lanting Capital, TF Capital and Vertex Ventures China. Regor Therapeutics was established with initial series A strategic investment from Qilu Pharmaceutical Group, a well-known Chinese pharmaceutical company.

"We are very pleased with the strong support from leading life science investment firms in this financing round. We are now in a strong position to advance pre-clinical and clinical studies of multiple programs," said Dr. Xiayang Qiu, Founder and CEO of Regor. "We are looking forward to long-term collaborations with our investors, as we aim to improve the treatment outcomes for worldwide patients of chronic diseases, cancer and other life-threatening diseases."

"We are proud to support Regor Therapeutics' world-class team to expand its efforts across a larger number of programs and therapeutic areas to develop tomorrow's life-saving treatments," said Dr. Yi Shi, managing partner of Lilly Asia Ventures.

"With the next decade comes a historical moment for China's leap upwards. We are delighted to collaborate with veteran scientists, leading entrepreneurs and investment partners in biopharma industry. Together we are working hard for a better world by innovative and transformative medicines which make meaningful impacts to patients globally," said Mr. Andy Lin, founding partner of Loyal Valley Capital.

삭제한 댓글은 다시 복구할 수 없습니다.
그래도 삭제하시겠습니까?
댓글 0
계정을 선택하시면 로그인·계정인증을 통해
댓글을 남기실 수 있습니다.